La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Axsome Therapeutics Gestione
Gestione criteri di controllo 2/4
Axsome Therapeutics' Il CEO è Herriot Tabuteau, nominato in Jan2012, e ha un mandato di 12.58 anni. la retribuzione annua totale è $ 9.90M, composta da 7.6% di stipendio e 92.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.015% delle azioni della società, per un valore di $ 622.91K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.3 anni e 9.7 anni.
Informazioni chiave
Herriot Tabuteau
Amministratore delegato
US$9.9m
Compenso totale
| Percentuale dello stipendio del CEO | 7.6% |
| Mandato del CEO | 12.6yrs |
| Proprietà del CEO | 0.02% |
| Durata media del management | 6.3yrs |
| Durata media del Consiglio di amministrazione | 9.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$309m |
| Mar 31 2024 | n/a | n/a | -US$296m |
| Dec 31 2023 | US$10m | US$750k | -US$239m |
| Sep 30 2023 | n/a | n/a | -US$202m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$8m | US$685k | -US$187m |
| Sep 30 2022 | n/a | n/a | -US$160m |
| Jun 30 2022 | n/a | n/a | -US$150m |
| Mar 31 2022 | n/a | n/a | -US$141m |
| Dec 31 2021 | US$8m | US$685k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$126m |
| Jun 30 2021 | n/a | n/a | -US$114m |
| Mar 31 2021 | n/a | n/a | -US$100m |
| Dec 31 2020 | US$7m | US$575k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$95m |
| Mar 31 2020 | n/a | n/a | -US$90m |
| Dec 31 2019 | US$5m | US$435k | -US$68m |
| Sep 30 2019 | n/a | n/a | -US$53m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$1m | US$435k | -US$31m |
| Sep 30 2018 | n/a | n/a | -US$29m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$1m | US$435k | -US$29m |
Compensazione vs Mercato: La retribuzione totale di Herriot ($USD 9.90M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.76M ).
Compensazione vs guadagni: La retribuzione di Herriot è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Herriot Tabuteau (56 yo)
12.6yrs
Mandato
US$9,896,629
Compensazione
Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 12.6yrs | US$9.90m | 0.015% $ 629.7k | |
| Chief Financial Officer | 6.3yrs | US$3.57m | 0.088% $ 3.7m | |
| Chief Operating Officer | 8.8yrs | US$4.04m | 0.012% $ 503.8k | |
| General Counsel & Secretary | 2.7yrs | US$3.06m | 0% $ 0 | |
| Executive VP & Head of Commercial | less than a year | Nessun dato | Nessun dato |
6.3yrs
Durata media
46.5yo
Età media
Gestione esperta: Il team dirigenziale di AXSM è esperto e expertise (durata media dell'incarico 6.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 12.6yrs | US$9.90m | 0.015% $ 629.7k | |
| Independent Lead Director | 9.7yrs | US$400.34k | 0.35% $ 14.6m | |
| Independent Director | 9.7yrs | US$405.34k | 0.021% $ 897.3k | |
| Independent Director | less than a year | US$417.48k | 0% $ 0 | |
| Independent Director | 9.7yrs | US$427.84k | 0.030% $ 1.3m |
9.7yrs
Durata media
56yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AXSM sono considerati esperti (durata media dell'incarico 9.7 anni).